home / stock / mrus / mrus articles
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company de...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company dev...
– Petosemtamab in combination with Keytruda 1L initial interim clinical data planned for 1H24; 2L+ HNSCC monotherapy clinical update planned 20...
Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer Poster: ...
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagriss...
News, Short Squeeze, Breakout and More Instantly...
Merus N.V. Company Name:
MRUS Stock Symbol:
NASDAQ Market:
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific anti...
2024-04-03 09:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg, M....